Home›Research›Compare›CJC-1295 (without DAC) vs IGF-2
Peptide ComparisonCJC-1295 (without DAC) vs IGF-2
Both are GH / IGF Axis peptides.
CJC-1295 (without DAC)
CJC-1295
Half-life: ~30 minutes
446 providers listed
IGF-2
Insulin-like Growth Factor 2
Half-life: ~10-20 minutes
No providers listed yet
IGF-2 carries stronger published evidence (Cohort study, 8 key studies) than CJC-1295 (without DAC) (Review, 1); both are research compounds.
CJC-1295 (without DAC)
Evidence
Half-life
~30 minutes
IGF-2
Evidence
Half-life
~10-20 minutes
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | IGF-2 |
| Less frequent dosing (longer half-life) | CJC-1295 (without DAC) |
| More provider options (446 vs 0) | CJC-1295 (without DAC) |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
CJC-1295 (without DAC)
IGF-2
CJC-1295 (without DAC)
IGF-2
An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling.
Paraneoplastic hypoglycemia as the initial presentation of a pancreatic neuroendocrine tumor.
Proteomics and ex vivo plaque culture identify the insulin-like growth factor axis as a potential regulator o…
The IGF signaling axis in thyroid cancer: biological complexity and therapeutic challenges.
+4 more
About CJC-1295 (without DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.
About IGF-2
Binds IGF-1R and insulin receptor variant A; promotes anabolic signaling in muscle and fat; activates PI3K/Akt/mTOR pathway; different receptor binding profile than IGF-1
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
CJC-1295 (without DAC)
Class-based (investigational)
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceIGF-2
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
CJC-1295 (without DAC)
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
CJC-1295 (without DAC)
IGF-2
Not enough vendor pricing yet.
Where to source these peptides
CJC-1295 (without DAC)
446 listed
Browse directory →
Providers offeringIGF-2
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More GH / IGF Axis Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). CJC-1295 (without DAC) vs IGF-2 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/igf-2